



# Business of Regenerative Medicine

Defining and creating value

July 15–16, 2019

Harvard Business School, Aldrich Hall

How does one 'define value' when considering a new technology? How does one create value when building a company on a novel platform? In today's market, how does one price innovation in different healthcare systems?

Join us for the 12th annual Business of Regenerative Medicine conference, where distinguished speakers will provide insights – as well as guardrails – for navigating the emerging industry of regenerative medicine.

Engage with CEOs, venture capitalists, experts in biomedical research, and patient advocates to explore how advances in cell and gene therapy, drug development, and bioengineering in regenerative medicine are moving from the lab to the patient – and what it will take to identify real, lasting value for business and society.

Speakers include:



**Sangeeta Bhatia, Ph.D.**  
Massachusetts Institute of  
Technology/Brigham and Women's  
Hospital




**Mark Fishman, M.D.**  
Harvard University



**George Church, Ph.D.**  
Harvard Medical School



**Geraldine Hamilton, Ph.D.**  
Emulate, Inc.



**George Q. Daley, M.D., Ph.D.**  
Harvard Medical School



**Paula Hammond, Ph.D.**  
Massachusetts Institute of  
Technology

**Program and registration: <https://brm2019.hsci.harvard.edu>**

The Business of Regenerative Medicine meeting series is organized and managed collaboratively by:  
Harvard Stem Cell Institute  
National Center for Regenerative Medicine, Case Western Reserve University  
CCRM: Commercializing Living Therapies  
Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Tech  
Institute for Regenerative Medicine, University of Pennsylvania

